Skip to main content
SpringerLink
Log in

Feline immunodeficiency virus infection: plasma, but not peripheral blood mononuclear cell virus titer is influenced by zidovudine and cyclosporine

  • Original Papers
  • Published:
Archives of Virology Aims and scope Submit manuscript

Summary

The plasma and peripheral blood mononuclear cell (PBMC) titer of feline immunodeficiency virus (FIV) in experimentally infected cats was assessed following administration of either zidovudine or cyclosporine. Treatments were begun 24 h post infection (p.i.) and continued for 4 weeks. Zidovudine treatment did not prevent establishment of infection with FIV, but plasma virus titers were significantly lower than controls at 2 weeks p.i. This reduction of plasma virus titer by zidovudine was not maintained at subsequent sampling times. Similarly, cyclosporine treatment initially lowered plasma virus titers at 2 weeks p.i., but at 4 weeks p.i. the plasma virus titers in cyclosporine-treated cats were significantly higher than in the untreated group. In the untreated group, plasma virus titers declined rapidly to an undetectable level by 14 weeks p.i. Neither zidovudine or cyclosporine treatment significantly influenced the titer of FIV in PBMCs. In all groups (untreated, zidovudine and cyclosporine) the titers in PBMC were high for the duration of the experiment. The decline in plasma virus titers in immunocompetent cats combined with the effect of cyclosporine on plasma titers strongly suggests that the immune system plays a major role in clearing FIV from plasma. In contrast, it appears that the immune response has little impact on PBMC virus titers. This shows that for complete assessment of antiviral agents, both cell-free and cell-associated virus titers must be examined. We also suggest that the limitation of viral titers in PBMC may be of critical importance in the control of lentiviral infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bagasra O, Hauptman SP, Lischner HW, Sachs M, Pomerantz RJ (1992) Detection of human immunodeficiency virus type 1 provirus in mononuclear cells by in situ polymerase chain reaction. N Engl J Med 326: 1385–1391

    Google Scholar 

  2. Boucher CAB, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JMA, Goudsmit J, Larder BA (1992) Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 165: 105–110

    Google Scholar 

  3. Centers for Disease Control (1990) Public health service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine post-exposure use. MMWR RR-1 39: 1–14

    Google Scholar 

  4. Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PJ, Kappes JC, Hahn BH, Shaw GM (1991) High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 324: 954–960

    Google Scholar 

  5. Daar ES, Moudgil T, Meyer RD, Ho DD (1991) Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 324: 961–964

    Google Scholar 

  6. Donovan RM, Dickover RE, Goldstein E, Huth RG, Carlson JR (1991) HIV-1 proviral copy number in blood mononuclear cells from AIDS patients on zidovudine therapy. J Acquir Immune Defic Syndr 4: 766–769

    Google Scholar 

  7. Durand E, Le Jeunne C, Hugues F-C (1991) Failure of prophylactic zidovudine after suicidal self-inoculation of HIV-infected blood. N Engl J Med 324: 1062

    Google Scholar 

  8. Fazely F, Haseltine WA, Rodger RF, Ruprecht RM (1991) Postexposure chemoprophylaxis with ZDV or ZDV combined with interferon-alpha: failure after inoculating rhesus monkeys with a high dose of SIV. J Acquir Immune Defic Syndr 4: 1093–1097

    Google Scholar 

  9. Greene WK, Meers J, Chadwick B, Carnegie PR, Robinson WF (1993) Nucleotide sequences of Australian isolates of the feline immunodeficiency virus: comparison with other feline lentiviruses. Arch Virol 132 (in press)

  10. Ho DD, Moudgil T, Alam M (1989) Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 321: 1621–1625

    Google Scholar 

  11. Hsia K, Spector SA (1991) Human immunodeficiency virus DNA is present in a high percentage of CD 4+ lymphocytes of seropositive individuals. J Infect Dis 164: 470–475

    Google Scholar 

  12. Hufert FT, Laer DV, Fenner TE, Schwander S, Kern P, Schmitz H (1991) Progression of HIV-1 infection. Monitoring of HIV-1 DNA in peripheral blood mononuclear cells by PCR. Arch Virol 120: 233–240

    Google Scholar 

  13. Jones PD (1991) HIV transmission by stabbing despite zidovudine prophylaxis. Lancet 338: 884

    Google Scholar 

  14. Kellam P, Boucher CAB, Larder BA (1992) Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high level resistance to zidovudine. Proc Natl Acad Sci USA 89: 1934–1938

    Google Scholar 

  15. Lange JMA, Boucher CAB, Hollak CEM, Wiltink EHH, Reiss P, van Royen EA, Roos M, Danner SA, Goudsmit J (1990) Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med 322: 1375–1377

    Google Scholar 

  16. Larder BA, Kemp SD (1989) Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155–1158

    Google Scholar 

  17. Looke DFM, Grove DI (1990) Failed prophylactic zidovudine after needlestick injury. Lancet 335: 1280

    Google Scholar 

  18. Lundgren B, Bottiger D, Ljungdahl-Stahle E, Norrby E, Stahle L, Wahren B, Oberg B (1991) Antiviral effects of 3′-fluorothymidine and 3′-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr 4: 489–498

    Google Scholar 

  19. Maki N, Miyazawa T, Fukasawa M, Hasegawa A, Hayami M, Miki K, Mikami T (1992) Molecular characterization and heterogeneity of feline immunodeficiency virus isolates. Arch Virol 123: 29–45

    Google Scholar 

  20. Marcus R, CDC Cooperative Needlestick Surveillance Group (1988) Surveillance of health care workers exposed to blood from patients infected with the human immunodeficiency virus. N Engl J Med 319: 1118–1123

    Google Scholar 

  21. McCune JM, Namikawa R, Shih C-C, Rabin L, Kaneshima H (1990) Suppression of HIV infection in AZT-treated SCID-hu mice. Science 247: 564–566

    Google Scholar 

  22. Meers J, Robinson WF, del Fierro GM, Scoones MA, Lawson MA (1992) Feline immunodefiency virus: quantification in peripheral blood mononuclear cells and isolation from plasma of infected cats. Arch Virol 127: 233–243

    Google Scholar 

  23. Niks M, Otto M (1990) Towards an optimized MTT assay. J Immunol Methods 130: 149–151

    Google Scholar 

  24. North TW, North GLT, Pedersen NC (1989) Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother 33: 915–919

    Google Scholar 

  25. Novotney C, English RV, Housman J, Davidson MG, Nasisse MP, Jeng CR, Davis WC, Tompkins MB (1990) Lymphocyte population changes in cats naturally infected with feline immunodeficiency virus. AIDS 4: 1213–1218

    Google Scholar 

  26. Olmsted RA, Langley R, Roelke ME, Goeken RM, Adger-Johnson D, Goff JP, Albert JP, Packer C, Laurenson MK, Caro TM, Scheepers L, Wildt DE, Bush M, Martenson JS, O'Brien SJ (1992) Worldwide prevalence of lentivirus infection in wild feline species: epidemiologic and phylogenetic aspects. J Virol 66: 6008–6018

    Google Scholar 

  27. Pedersen NC, Barlough JE (1991) Clinical overview of feline immunodeficiency virus. J Am Vet Med Assoc 199: 1298–1305

    Google Scholar 

  28. Perryman LE, O'Rourke KI, McGuire TC (1988) Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection. J Virol 62: 3073–3076

    Google Scholar 

  29. Phillips TR, Talbott RL, Lamont C, Muir S, Lovelace K, Elder JH (1990) Comparison of two host cell range variants of feline immunodeficiency virus. J Virol 64: 4605–4613

    Google Scholar 

  30. Remington KM, Chesebro B, Wehrly K, Pedersen NC, North TW (1991) Mutants of feline immunodeficiency virus resistant to 3′-azido-3′-deoxythymidine. J Virol 65: 308–312

    Google Scholar 

  31. Ruprecht RM, O'Brien LG, Rossoni LD, Nusinoff-Lehrman S (1986) Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidine. Nature 323: 467–469

    Google Scholar 

  32. Shih C-C, Kaneshima H, Rabin L, Namikawa R, Sager P, McGowan J, McCune JM (1991) Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner. J Infect Dis 163: 625–627

    Google Scholar 

  33. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA (1990) HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 9: 1551–1560

    Google Scholar 

  34. St Georgiev V (1991) Immunomodulating peptides of natural and synthetic origin. Med Res Rev 11: 81–119

    Google Scholar 

  35. Talbott RL, Sparger EE, Lovelace KM, Fitch WM, Pedersen NC, Luciw PA, Elder JH (1989) Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci USA 86: 5743–5747

    Google Scholar 

  36. Tavares L, Roneker C, Johnston K, Nusinoff-Lehrman S (1987) 3′-azido-3′deoxythymidine in feline leukaemia virus-infected cats: a model for therapy and prophylaxis of AIDS. Cancer Res 47: 3190–3194

    Google Scholar 

  37. Torten M, Franchini M, Barlough JE, George JW, Mozes E, Lutz H, Pedersen NC (1991) Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus. J Virol 65: 2225–2230

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Veterinary Studies, Murdoch University, Murdoch, Australia

    Joanne Meers, G. M. del Fierro, R. B. Cope, H. S. Park, W. K. Greene & W. F. Robinson

Authors
  1. Joanne Meers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. M. del Fierro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. B. Cope
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. S. Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W. K. Greene
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. F. Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meers, J., del Fierro, G.M., Cope, R.B. et al. Feline immunodeficiency virus infection: plasma, but not peripheral blood mononuclear cell virus titer is influenced by zidovudine and cyclosporine. Archives of Virology 132, 67–81 (1993). https://doi.org/10.1007/BF01309844

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01309844

Keywords

Search

Navigation